| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| Other Sizes |
| Targets |
5'-O-DMT-2'-O-TBDMS-N-Bz-Adenosine does not have a specific biological target itself but serves as a protected adenosine building block for oligonucleotide synthesis. When incorporated into oligonucleotides, the resulting sequences can target various biological molecules. The multiple protecting groups (DMT at 5'-position, TBDMS at 2'-position, benzoyl at N6-position) allow for selective deprotection and controlled synthesis of modified oligonucleotides. The TBDMS group at the 2'-position is commonly used in RNA synthesis to differentiate the 2'-hydroxyl from the 3'-hydroxyl.
|
|---|---|
| ln Vitro |
In vitro activity of 5'-O-DMT-2'-O-TBDMS-N-Bz-Adenosine is assessed by its utility as a building block in oligonucleotide synthesis. The efficiency of incorporation into growing oligonucleotide chains during solid-phase synthesis is evaluated by monitoring coupling efficiency through trityl cation release measurements. The purity of the compound and its suitability for automated oligonucleotide synthesis are assessed by HPLC analysis. The resulting oligonucleotides are evaluated for their ability to hybridize to complementary sequences using thermal melting (Tm) analysis.
|
| ln Vivo |
In vivo studies for 5'-O-DMT-2'-O-TBDMS-N-Bz-Adenosine are typically conducted on the oligonucleotides synthesized using this building block rather than the protected nucleoside itself. These oligonucleotides are evaluated in animal models for their pharmacokinetic properties, biodistribution, and therapeutic efficacy in applications such as antisense therapy or RNA-based therapeutics. The protecting groups are removed during oligonucleotide synthesis and deprotection, so the final oligonucleotide contains the natural adenosine nucleoside.
|
| Enzyme Assay |
For oligonucleotide synthesis, 5'-O-DMT-2'-O-TBDMS-N-Bz-Adenosine is converted to the corresponding phosphoramidite and incorporated into oligonucleotides using standard solid-phase synthesis protocols. The compound is dissolved in anhydrous acetonitrile and coupled to the growing oligonucleotide chain. Coupling efficiency is monitored by trityl cation release measurements at each synthesis cycle. After synthesis, the oligonucleotide is cleaved from the solid support and deprotected using appropriate reagents. The TBDMS group is typically removed using fluoride-based reagents such as TBAF. The final oligonucleotide is purified by HPLC or PAGE and characterized by mass spectrometry.
|
| Cell Assay |
For cellular studies, cultured cells are treated with oligonucleotides synthesized using 5'-O-DMT-2'-O-TBDMS-N-Bz-Adenosine as a building block. Cells are incubated with oligonucleotides for 24-72 hours, and cellular uptake is assessed by fluorescence microscopy or flow cytometry using fluorescently labeled oligonucleotides. For antisense applications, gene knockdown efficiency is evaluated by qRT-PCR or Western blot. For aptamer applications, binding to target proteins is assessed by surface plasmon resonance or ELISA. Cytotoxicity is assessed using MTT or CellTiter-Glo assays.
|
| Animal Protocol |
For in vivo evaluation of oligonucleotides synthesized using 5'-O-DMT-2'-O-TBDMS-N-Bz-Adenosine, mice or rats are administered the oligonucleotides via various routes. Pharmacokinetic parameters including half-life, clearance, and tissue distribution are determined by measuring oligonucleotide concentrations in plasma and tissues using hybridization-based assays or LC-MS. For therapeutic applications, efficacy is evaluated in appropriate disease models (e.g., tumor xenografts for antisense therapy), with tumor volume or disease biomarkers monitored over time. Toxicity is assessed by monitoring body weight, organ histopathology, and serum chemistry.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 5'-O-DMT-2'-O-TBDMS-N-Bz-Adenosine are characterized for the oligonucleotides incorporating this building block rather than the protected nucleoside itself. The compound has a molecular weight of 787.97 and is typically handled as a solid. The TBDMS protecting group enables selective RNA synthesis by protecting the 2'-hydroxyl. Detailed PK parameters depend on the specific oligonucleotide sequence, length, and backbone chemistry. Storage at -20°C under inert gas is recommended.
|
| Toxicity/Toxicokinetics |
5'-O-DMT-2'-O-TBDMS-N-Bz-Adenosine is a research compound intended for laboratory use only and is not approved for human therapeutic use. As an adenosine derivative, it serves as an intermediate in oligonucleotide synthesis. The compound features DMT, TBDMS, and benzoyl protecting groups. Standard laboratory safety precautions should be followed when handling this compound. Storage at -20°C under inert gas is recommended.
|
| Additional Infomation |
5'-O-DMT-2'-O-TBDMS-N-Bz-Adenosine is an adenosine derivative with molecular formula C44H49N5O7Si and molecular weight 787.97. It serves as an intermediate in oligonucleotide synthesis, featuring DMT protection at the 5'-position, TBDMS protection at the 2'-position (for RNA synthesis), and benzoyl protection at the N6-position of adenine. The compound is for research use only and has not been approved for clinical applications. Storage at -20°C under inert gas is recommended.
|
| Molecular Formula |
C44H49N5O7SI
|
|---|---|
| Molecular Weight |
787.97
|
| Exact Mass |
787.34
|
| CAS # |
81265-93-2
|
| PubChem CID |
13871229
|
| Appearance |
White to off-white solid powder
|
| LogP |
7.826
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
14
|
| Heavy Atom Count |
57
|
| Complexity |
1250
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
CC(C)(C)[Si](C)(C)O[C@@H]1[C@@H]([C@H](O[C@H]1N2C=NC3=C(N=CN=C32)NC(=O)C4=CC=CC=C4)COC(C5=CC=CC=C5)(C6=CC=C(C=C6)OC)C7=CC=C(C=C7)OC)O
|
| InChi Key |
DAZIGOPASNJPCJ-GNECSJIWSA-N
|
| InChi Code |
InChI=1S/C44H49N5O7Si/c1-43(2,3)57(6,7)56-38-37(50)35(55-42(38)49-28-47-36-39(45-27-46-40(36)49)48-41(51)29-14-10-8-11-15-29)26-54-44(30-16-12-9-13-17-30,31-18-22-33(52-4)23-19-31)32-20-24-34(53-5)25-21-32/h8-25,27-28,35,37-38,42,50H,26H2,1-7H3,(H,45,46,48,51)/t35-,37-,38-,42-/m1/s1
|
| Chemical Name |
N-[9-[(2R,3R,4R,5R)-5-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-3-[tert-butyl(dimethyl)silyl]oxy-4-hydroxyoxolan-2-yl]purin-6-yl]benzamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). This product is not stable in solution, please use freshly prepared working solution for optimal results. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 50 mg/mL (63.45 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (3.17 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.17 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2691 mL | 6.3454 mL | 12.6908 mL | |
| 5 mM | 0.2538 mL | 1.2691 mL | 2.5382 mL | |
| 10 mM | 0.1269 mL | 0.6345 mL | 1.2691 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
